Moving from 1mg to 1.7mg Wegovy: what happens at this dose step

What the licensed titration schedule actually says about 1.7mg

Wegovy's titration pathway (confirmed in its Summary of Product Characteristics published on the electronic Medicines Compendium) runs from 0.25mg through 0.5mg, 1mg, 1.7mg and finally 2.4mg, with a minimum of four weeks at each level. The NHS medicines page for semaglutide describes this schedule clearly and is the best plain-language reference for patients wanting to understand why the escalation exists at all.

The reasoning is straightforward. Semaglutide slows gastric emptying and acts on appetite-regulating centres in the brain; both effects intensify as the dose rises. Stepping up gradually gives the gut and the nervous system time to adjust. At 1mg, most people have already moved through the most turbulent early weeks. The 1.7mg pen is the bridge to maintenance dose — therapeutically meaningful, but not yet the ceiling.

One misconception worth letting go gently: some people believe that if they tolerated 1mg without difficulty they should be able to skip straight to 2.4mg. The schedule doesn't work that way. Each step has its own tolerability profile, and the 1.7mg period is a genuine part of treatment, not a formality to clear in a hurry. A prescriber will confirm readiness to move up before any change is made.

If you are comparing this step to earlier transitions, the jump from 0.25mg to 0.5mg tends to be the one people remember most vividly for nausea; by the time 1.7mg arrives, most people have found their rhythm with the injection.

How the evidence describes what happens at higher doses

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. Participants reached the 2.4mg maintenance dose through the same stepwise schedule, meaning every participant passed through the 1.7mg step. Average weight reduction at the end of the study was around 15%, with around a third of participants losing more than 20% of their starting weight. No single dose produced all of that; the accumulating effect built across the escalation period.

What this tells us about the 1mg-to-1.7mg step specifically is that it is part of a trajectory, not an endpoint. NICE's appraisal of semaglutide (TA875) supports the medicine within a structured weight management programme, and the clinical evidence it relied on was largely generated through this graduated approach. Skipping steps or rushing them was not part of the study design, which is partly why prescribers follow the schedule closely.

The move from 1.7mg to 2.4mg follows the same four-week minimum wait and is again a prescriber decision. Understanding where the 1.7mg step fits in that broader arc makes it easier to see it for what it is: evidence-based pacing, not delay. For a fuller picture of what Wegovy treatment involves from start to finish, the Wegovy overview covers the whole journey.

Side effects at the 1.7mg step and how they typically unfold

The side-effect profile at 1.7mg is consistent with the rest of the titration: gastrointestinal symptoms dominate. Nausea, loose stools, constipation, indigestion and reflux are the most commonly reported, and they tend to peak in the first one to two weeks after the increase before easing off. This pattern was consistent across the STEP programme and is reflected in the NHS patient information for semaglutide.

A practical note: side effects at this step are generally less intense than at the very first injection, because the body has had months of gradual adjustment by now. That said, individual experience varies, and some people find 1.7mg brings a brief return of nausea they thought was behind them.

If you are considering whether the cost of continuing through this stage is worthwhile, the Wegovy pricing page sets out what private treatment involves, including what a single transparent price should cover. What matters at the 1.7mg step, though, is staying in contact with your prescriber. Symptoms that are severe, persistent, or include serious stomach pain spreading to the back warrant urgent medical attention; the MHRA has specifically highlighted acute pancreatitis as a rare but serious risk with GLP-1 medicines, and any such symptom should be checked promptly.

Yellow Card reporting is available at yellowcard.mhra.gov.uk if you experience a side effect you want to report formally.

What a prescriber looks at before confirming the move to 1.7mg

The four-week minimum is the floor, not the automatic trigger. A clinician reviewing your case will want to know how 1mg sat with you, whether side effects settled, whether you managed to maintain adequate nutrition and hydration, and whether there are any reasons to hold at the current dose for longer. People with persistent gastrointestinal symptoms sometimes benefit from an extended period at 1mg before moving up; that call belongs to the prescriber.

At nume, every dose change is reviewed by a GPhC-registered Independent Prescriber before anything is dispensed. There are no automated approvals; evidence of your current treatment and your response to it informs every repeat. If you are at the point of considering your next step and want that kind of clinical oversight, how dose increases work at nume explains the process in plain terms.

For those still earlier in the journey, the 1mg to 1.7mg transition page covers similar ground with a slightly different focus on preparation, and whether earlier steps can be combined is addressed separately. The short answer to that last question is: not without a prescriber agreeing it is safe. Start your free consultation with our clinical team if you'd like a personalised assessment of where you are in treatment.